Skip to Content

Thomas A Buchholz, M.D., F.A.C.R., F.A.S.T.R.O

Present Title & Affiliation

Primary Appointment

Executive Vice President & Physician in Chief, The University of Texas MD Anderson Cancer Center, Houston, TX
Hubert L. Olive Stringer Distinguished Chair in Oncology in Honor of Sue Gribble Stringer, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor (tenure), Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Buchholz is Professor, Executive Vice President and Physician-in-Chief at The University of Texas MD Anderson Cancer Center. He holds the Hubert L. Stringer Distinguished Chair in Oncology in Honor of Sue Gribble Stringer.  In his role as Physician-in-Chief Dr. Buchholz is responsible for the clinical faculty and operating of MD Anderson's Houston hospital and ambulatory clinics. His academic interests focus on clinical and translational research in breast cancer and radiation oncology.  Finally, Dr. Buchholz has a strong interest in education and mentoring junior faculty and trainees in clinical care and clinical/translational research. 

Education & Training

Degree-Granting Education

1988 Tufts University School of Medicine, Boston, MA, MD, Medicine
1984 Bucknell University, Lewisburg, PA, BA, Philosophy

Postgraduate Training

1/2005-12/2005 Faculty Leadership Training, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1992-6/1993 Research Fellowship, Radiobiology Research, University of Washington Medical Center, Seattle, WA, George E. Laramore, M.D., Ph.D., Janet S. Rasey, P
7/1989-6/1992 Clinical Residency, Radiation Oncology, University of Washington Medical Center, Seattle, WA, Wui-Jin Koh, M.D.
7/1988-6/1989 Clinical Internship, Medical Internship, Mount Auburn Hospital, Cambridge, MA, Charles Hatem, M.D.

Board Certifications

6/1993 American Board of Radiology (Radiation Oncology)
1/1989 National Board of Medical Examiners


Administrative Appointments/Responsibilities

Provost and Executive Vice President ad-interim, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2012-7/2013
Division Head, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2011-1/2014
Department Chair, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2/2007-1/2014

Honors and Awards

2011 Consumers' Checkbook's Top Doctor, Doximity
2010 Fellow, American Society for Therapeutic Radiation Oncology, American Society for Therapeutic Radiation Oncology
2008 Fellow, American College of Radiology, American College of Radiology
2003-2014 Top Doctors in America/America's Top Doctors, Castle Connolly Medical Ltd

Selected Publications

Peer-Reviewed Original Research Articles

1. Thaker NG, Hoffman KE, Stauder MC, Shaitelman SF, Strom EA, Tereffe W, Smith BD, Perkins GH, Huo L, Munsell MF, Pustzai L, Buchholz TA, Woodward WA. The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. Springerplus. e-Pub 1/2015. PMID: 25674496.
2. Shaitelman SF, Buchholz TA, Hunt KK, Hortobagyi GN, Schlembach P, Arzu I, Bloom E, Chronowski G, Dvorak T, Grade E, Hoffman KE, Perkins GH, Reed V, Shah S, Stauder MC, Strom EA, Tereffe W, Woodward WA, Ensor J, Smith BD. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compated to conventionally fractionated whole breast irradiation: results of a randomized Trial. Int J Radiat Oncol Biol Phys 90(5):1264, 12/2014. PMID: 25539386.
3. Hoffman KE, Niu J, Shen Y, Jiang J, Davis JW, Kim J, Kuban DA, Perkins GH, Shah JB, Smith GL, Volk RJ, Buchholz TA, Giordano SH, Smith BD. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med 174(9):1450-9, 9/2014. PMID: 25023650.
4. Barcenas CH, Niu J, Zhang N, Zhang Y, Buchholz TA, Elting LS, Hortobagyi GN, Smith BD, Giordano SH. Risk of hospitalization by chemotherapy regiment in early starge breast cancer. J Clin Oncol 32(19):2010-7, 7/1/2014. e-Pub 5/27/2014. PMID: 24868022.
5. Eberth JM, Xu Y, Smith GL, Shen Y, Jiang J, Buchholz TA, Hunt KK, Black DM, Giordano SH, Whitman GJ, Yang W, Shen C, Elting L, Smith BD. Surgeon influence on use of needle biopsy in patients with breast cancer; A National Medicare Study. J Clin Oncol 32(21):2206-16, 7/20/2014. e-Pub 6/9/2014. PMID: 24912900.
6. Guadagnolo BA, Liao KP, Giordano SH, Elting LS, Buchholz TA, Shih YC. Increasing use of advanced radiation therapy technologies in the last 30 days of life among patients dying as a result of cancer in the United States. J Oncol Pract 10(4):e269-76, 7/2014. e-Pub 4/22/2014. PMCID: PMC4094648.
7. Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu W, Hortobágyi GN, Buchholz TA, Ueno NT, Woodward WA. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med 3(7):849-56, 7/2014. e-Pub 5/15/2014. PMCID: PMC4073823.
8. McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment. Int J Radiat Oncol Biol Phys 89(2):392-8, 6/1/2014. e-Pub 4/7/2014. PMID: 24721590.
9. Yang J, Woodward WA, Reed VK, Strom EA, Perkins GH, Tereffe W, Buchholz TA, Zhang L, Balter P, Court LE, Li XA, Dong L. Statistical modeling approach to quantitative analysis on inter-observer variability in breast contouring. Int J Radiat Oncol Biol Phys 89(1):214-21, 5/1/2014. e-Pub 3/7/2014. PMCID: PMC3997068.
10. Buchholz TA, Somerfield MR, Griggs JJ, El-Eid S, Hammond ME, Lyman GH, Mason G, Newman LA. Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: American Society of Clinical Oncology Endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology Consensus Guideline. J Clin Oncol 32(14):1502-6, 5/2014. e-Pub 4/2014. PMID: 24711553.
11. Woodward WA, Krishnamurthy S, Lodhi A, Xiao L, gong Y, Cristofanilli M, Buchholz TA, Lucci A. Aldehyde dehydrogenase 1 immunohistochemical staining in primary breast cancer cells independently predicted overall survival but did not correlate with the presence of circulating or disseminated tumor cells. J Cancer 5(5):360-367, 4/2014. PMID: 24799954.
12. Huo J, Lairson DR, Du XL, Chan W, Jiang J, Buchholz TA, Guadagnolo BA. Hospital case volume is associated with improved survival for patients with metastatic melanoma. Am J Clin Oncol. e-Pub 4/2014. PMID: 24755661.
13. MacDermed DM, Houtman KM, Thang SH, Allen PK, Caudle AS, Gainer SM, Hunt KK, Perkins GH, Shaitelman SF, Smith BD, Strom EA, Tereffe W, Woodward WA, Buchholz TA, Hoffman K. Therapeutic radiation dose delivered to the low axilla during whole breast radiotherapy in the prone posistion: implications for targeting the undissected axilla. Practical Radiation Oncology 4(2):116-122, 4/2014. PMID: 24890352.
14. Beadle BM, Liao KP, Elting LS, Buchholz TA, Ang KK, Garden AS, Guadagnolo BA. Improved survival using intensity-modulated radiation therapy in head and neck cancers: a SEER-Medicare analysis. Cancer 120(5):702-10, 3/2014. e-Pub 1/2014. PMID: 24421077.
15. Jagsi R, Jiang J, Momoh AO, Alderman A, Giordano SH, Buchholz TA, Kronowitz SJ, Smith BD. Trends and variation in use of breast reconstruction in breast cancer patients undergoing mastectomy in the United States. J Clin Oncol 32(9):919-26, 3/2014. e-Pub 2/2014. PMID: 24550418.
16. Smith GL, Jiang J, Buchholz TA, Xu Y, Hoffman KE, Giordano SH, Hunt KK, Smith BD. Benefit of adjuvant brachytherapy versus external beam radiation for early breast cancer: Impact of patient stratification on breast preservation. Int J Radiat Oncol Biol Phys 88(2):274-84, 2/2014. e-Pub 11/2013. PMCID: PMC3947195.
17. Mason KA, Raju U, Buchholz TA, Wang L, Milas ZL, Milas L. Poly (ACP-ribose) polymerase inhibitors in cancer treatment. Am J Clin Oncol 37(1):90-100, 2/2014. e-Pub 4/2012. PMID: 22495455.
18. Ost DE, Niu J, S Elting L, Buchholz TA, Giordano SH. Quality Gaps and Comparative Effectiveness in Lung Cancer Staging and Diagnosis. Chest 145(2):331-45, 2/2014. e-Pub 10/2013. PMID: 24091637.
19. Takiar V, Akay CL, Stauder MC, Tereffe W, Alvarez RH, Hoffman KE, Perkins GH, Strom EA, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. Springerplus 3:166, 2014. e-Pub 3/2014. PMCID: PMC3977020.
20. Carkaci S, Sherman CT, Ozkan E, Adrada BE, Wei W, Rohren EM, Mawlawi OR, Ueno NT, Buchholz TA, Yang WT. F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 40(12):1809-16, 12/2013. e-Pub 7/23/2013. PMID: 23877633.
21. Beadle BM, Liao KP, Chambers MS, Elting LS, Buchholz TA, Kian Ang K, Garden AS, Guadagnolo BA. Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: A SEER-Medicare analysis. Head Neck 35(11):1599-605, 11/2013. e-Pub 11/14/2012. PMID: 23150453.
22. Shirvani SM, Jiang J, Gomez DR, Chang JY, Buchholz TA, Smith BD. Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: Predictors of use and association with toxicities. Lung Cancer 82(2):252-9, 11/2013. e-Pub 8/2013. PMCID: PMC3839043.
23. Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH. Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer. J Clin Oncol 31(33):4222-8, 11/2013. e-Pub 10/2013. PMCID: PMC3821011.
24. Guan X, Liu H, Ju J, Li Y, Li P, Wang LE, Brewster AM, Buchholz TA, Arun BK, Wei Q, Liu Z. Genetic variant rs 16430 6bp & gt; 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in no-hispanic white women aged <55 years. Mol Carcinog. e-Pub 10/26/2013. PMID: 24166930.
25. Haffty BG, Buchholz TA. Hypofractionated breast radiation: preferred standard of care? Lancet Oncol 14(11). e-Pub 10/2013. PMID: 24079860.
26. Weksberg DC, Allen PK, Hoffman KE, Litton JK, Strom EA, Shah RR, Kuerer HM, Hunt KK, Buchholz TA, Mittendorf EA. Outcomes and predictive factors for salvage therapy after local-regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol 20(11):3430-7, 10/2013. e-Pub 5/2013. PMID: 23720073.
27. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK, for the Alliance for Clinical Trials in Oncology. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial. JAMA 310(14):1455-1461, 10/2013. e-Pub 10/2013. PMID: 24101169.
28. Famiglietti RM, Neal EC, Edwards TJ, Allen PK, Buchholz TA. Determinants of patient satisfaction during receipt of radiation therapy. Int J Radiat Oncol Biol Phys 87(1):148-152, 9/1/2013. PMID: 23920394.
29. Sheu T, Molkentine J, Transtrum MK, Buchholz TA, Withers HR, Thames HD, Mason KA. Use of the LQ model with large fraction sizes results in underestimation of isoeffect doses. Radiother Oncol. e-Pub 9/20/2013. PMID: 24060173.
30. Wang X, Zhang X, Li X, Amos RA, Shaitelman SF, Hoffman K, Howell R, Salehpour M, Zhang SX, Sun TL, Smith B, Tereffe W, Perkins GH, Buchholz TA, Strom EA, Woodward WA. Accelerated partial-breast irradiation using intensity-modulated proton radiotherapy: do uncertainties outweigh potential benefits? Br J Radiol 86(1029):20130176, 9/2013. e-Pub 5/31/2013. PMCID: PMC3755395.
31. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with Trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 24(8):1999-2004, 8/2013. e-Pub 4/2013. PMCID: PMC3718505.
32. Walker GV, Giordano SH, Williams M, Jiang J, Niu J, MacKinnon J, Anderson P, Wohler B, Sinclair AH, Boscoe FP, Schymura MJ, Buchholz TA, Smith BD. Muddy Water? Variation in reporting receipt of breast cancer radiation therapy by population-based tumor registries. Int J Radiat Oncol Biol Phys 86(4):686-693, 7/15/2013. PMID: 23773392.
33. Das P, Johnson J, Hayden SE, Riley BA, Harrelson S, Gillin M, Ibbott G, Buchholz TA. Rate of radiation therapy events in a large academic institution. J Am Coll Radiol 10(6):452-455, 6/2013. PMID: 23735271.
34. Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Yang W, Cristofanilli M, Valero V, Buchholz TA. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy. Am J Clin Oncol. e-Pub 5/2/2013. PMID: 23648437.
35. Huo J, Du XL, Lairson DR, Chan W, Jiang J, Buchholz TA, Guadagnolo BA. Utilization of surgery, chemotherapy, radiation therapy, and hospice at the end of life for patients diagnosed with metastatic melanoma. Am J Clin Oncol. e-Pub 5/2/2013. PMCID: PMC3796177.
36. Yi M, Cormier JN, Xing Y, Giordano SH, Chai C, Meric-Bernstam F, Vlastos G, Kuerer HM, Mirza NQ, Buchholz TA, Hunt KK. Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy. Ann Surg Oncol 20(5):1514-21, 5/2013. e-Pub 12/6/2012. PMID: 23224829.
37. Guadagnolo BA, Huo J, Liao KP, Buchholz TA, Das P. Changing trends in radiation therapy technologies in the last year of life for patients diagnosed with metastatic cancer in the United States. Cancer 119(5):1089-1097, 3/1/2013. e-Pub 11/6/2012. PMCID: PMC3688625.
38. Albert JM, Buchholz TA, Smith BD. Reply to P.G. Tsoutsou et al. J Clin Oncol 5(648-649):648-9, 2/10/2013. e-Pub 2/2013. PMID: 23520644.
39. Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera GV, Hoffman K, Yi M, Ross MI, Hortobagyi GN, Hunt KK. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg 257(2):173-179, 2/2013. PMID: 23291658.
40. Guadagnolo BA, Liao KP, Elting L, Giordano S, Buchholz TA, Shih YC. Use of Radiation Therapy in the Last 30 Days of Life Among a Large Population-Based Cohort of Elderly Patients in the United States. J Clin Oncol 31(1):80-87, 1/1/2013. e-Pub 11/19/2012. PMCID: PMC3530693.
41. Lynch SP, Lei X, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang H, Hortobágyi GN, Gonzalez-Angulo AM, Valero V. Breast cancer multifocality and multicentricity and locoregional recurrence. Oncologist 18(11):1167-73, 2013. e-Pub 10/17/2013. PMCID: PMC3825299.
42. Skinner HD, Strom EA, Motwani SB, Woodward WA, Green MC, Babiera G, Booser DJ, Meric-Bernstam F, Buchholz TA. Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy. Radiat Oncol 8(1):13, 2013. e-Pub 1/11/2013. PMCID: PMC3552737.
43. Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 84(5):1060-70, 12/1/2012. e-Pub 9/11/2012. PMCID: PMC3776428.
44. Kong AL, Tereffe W, Hunt KK, Yi M, Kang T, Weatherspoon K, Mittendorf EA, Bedrosian I, Hwang RF, Babiera GV, Buchholz TA, Meric-Bernstam F. Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer 118(24):6287-6296, 12/15/2012. e-Pub 5/30/2012. PMID: 22648744.
45. Lynch SP, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 23(12):3063-3069, 12/2012. e-Pub 7/9/2012. PMCID: PMC3501230.
46. Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, Buchholz TA, Woodward WA. Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WTN/B-catenin. Stem Cells 30(11):2366-2377, 11/2012. e-Pub 9/2012. PMID: 22961641.
47. Albert JM, Pan IW, Shih YC, Jiang J, Buchholz TA, Giordano SH, Smith BD. Effectiveness of radiation for prevention of mastectomy in older breast cancer patients treated with conservative surgery. Cancer 118(19):4642-51, 10/1/2012. e-Pub 8/13/2012. PMID: 22890779.
48. Kim MM, Dawood S, Allen P, Sahin AA, Woodward WA, Smith BD, Strom EA, Hunt KK, Meric-Bernstam F, Gonzalez-Angulo AM, Buchholz TA. Hormone receptor status influences the locoregional benefit of Trastuzumab in patients with non-metastatic breast cancer. Cancer 118(20):4936-43, 10/15/2012. e-Pub 4/17/2012. PMID: 22511276.
49. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer 118(19):4652-9, 10/1/2012. e-Pub 2/22/2012. PMID: 22359359.
50. Guadagnolo BA, Xu Y, Zagars GK, Cormier JN, Pollock RE, Feig BW, Giordano S, Buchholz TA, Shih YC. A Population-Based Study of the Quality of Care in the Diagnosis of Large (≥5 cm) Soft Tissue Sarcomas. Am J Clin Oncol 35(5):455-61, 10/2012. e-Pub 4/29/2011. PMID: 21537147.
51. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer 12(5):364-72, 10/2012. PMID: 23040004.
52. Hunt KK, Ballman KV, McCall LM, Boughey JC, Mittendorf EA, Cox CE, Whitworth PW, Beitsch PD, Leitch AM, Buchholz TA, Morrow MA, Giuliano AE. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg 256(3):428-36, 9/2012. e-Pub 8/2012. PMID: 22868365.
53. Albert JM, Liu DD, Shen Y, Pan IW, Shih YC, Hoffman KE, Buchholz TA, Giordano SH, Smith BD. Nomogram to predict the benefit of radiation for older breast cancer patients treated with conservative surgery. J Clin Oncol 30(23):2837-2843, 8/10/2012. e-Pub 6/25/2012. PMCID: PMC3410401.
54. Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A, Ueno NT, Buchholz TA. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field design. Int J Radiat Oncol Biol Phys 83(5):1381-1386, 8/1/2012. e-Pub 1/26/2012. PMID: 22284689.
55. Pinnix C, Perkins GH, Strom EA, Tereffe W, Woodward W, Oh JL, Arriaga L, Munsell MF, Kelly P, Hoffman KE, Smith BD, Buchholz TA, Yu TK. Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial. Int J Radiat Oncol Biol Phys 83(4):1089-1094, 7/15/2012. e-Pub 12/14/2011. PMID: 22172912.
56. Smith BD, Smith GL, Buchholz TA. Brachytherapy vx whole-breast irradiation: trial by data. Int J Radiat Oncol Biol Phys 83(4):1078-1080, 7/2012. PMID: 22704702.
57. Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, Reuben JM, Cristofanilli M, Buchholz TA, Woodward WA. Pre-clinical studies of notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat 134(2):495-510, 7/2012. e-Pub 5/1/2012. PMID: 22547109.
58. Dawood S, Shaikh AJ, Buchholz TA, Cortes J, Cristofanilli M, Gupta S, Gonzalez-Angulo AM. The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancer 118(11):2780-2786, 6/1/2012. e-Pub 10/5/2011. PMID: 22614656.
59. Hoffman KE, Mittendorf EA, Buchholz TA. Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy. Lancet Oncol 13(6):e270-e276, 6/2012. PMID: 22652235.
60. Smith GL, Xu Y, Buchholz TA, Giordano SH, Jiang J, Shih YC, Smith BD. Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA 307(17):1827-1837, 5/2/2012. PMCID: PMC3397792.
61. Cheng L, Swartz MD, Zhao H, Kapadia AS, Lai D, Rowan PJ, Buchholz TA, Giordano SH. Hazard of recurrent among women after primary breast cancer treatment – a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev 21(5):800-809, 5/2012. e-Pub 3/16/2012. PMID: 22426147.
62. Carkaci S, Adrada BE, Rohren E, Wei W, Quraishi MA, Mawlawi O, Buchholz TA, Yang W. Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: Is there a reliable threshold for differentiating benign from malignant? Acad Radiol 19(5):535-41, 5/2012. e-Pub 2/1/2012. PMID: 22300741.
63. Wang LE, Han CH, Xiong P, Bondy ML, Yu TK, Brewster AM, Shete S, Arun BK, Buchholz TA, Wei Q. Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study. Breast Cancer Res Treat 132(3):1147-55, 4/2012. e-Pub 1/5/2012. PMCID: PMC3523666.
64. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol 23(4):870-5, 4/2012. e-Pub 7/15/2011. PMID: 21765048.
65. Wu Y, Mittendorf EA, Kelten C, Tucker SL, Wei W, Middleton LP, Broglio K, Buchholz TA, Hunt KK, Sahin AA. Occult axillary lymph node metastasis do not have prognostic significance in early stage breast cancer. Cancer 118(6):1507-14, 3/15/2012. e-Pub 8/25/2011. PMID: 22009292.
66. Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I, Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 19(3):901-907, 3/2012. e-Pub 8/23/2011. PMID: 21861223.
67. Wang X, Pan T, Pinnix C, Zhang SX, Salehpour M, Sun TL, Gladish G, Strom EA, Perkins GH, Tereffe W, Woodward W, Hoffman KE, Buchholz TA, Yu TK. Cardiac motion during deep-inspiration breath-hold: implications for breast cancer radiotherapy. Int J Radiat Oncol Biol Phys 82(2):708-14, 2/1/2012. e-Pub 3/26/2011. PMID: 21444161.
68. Chien CR, Pan IW, Tsai YW, Tsai T, Liang JA, Buchholz TA, Shih YC. Radiation Therapy After Breast-Conserving Surgery: Does Hospital Surgical Volume Matter? A Population-Based Study in Taiwan. Int J Radiat Oncol Biol Phys 82(1):43-50, 1/1/2012. e-Pub 11/13/2010. PMID: 21075558.
69. Barcenas CH, Zhang N, Zhao H, Duan Z, Buchholz TA, Hortobagyi GN, Giordano SH. Anthracycline regimen adherencein older patients with early breast cancer. Oncologist 17(3):303-11, 2012. e-Pub 2/27/2012. PMCID: PMC3316913.
70. McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA. CENP-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res 14(3):R72, 2012. e-Pub 5/4/2012. PMCID: PMC3446334.
71. Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, Hunt KK, Brewster A, Babiera GV, Buchholz TA, Meric-Bernstam F, Bedrosian I. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res 14(3):R82, 2012. e-Pub 5/23/2012. PMCID: PMC3446345.
72. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobágyi GN, Ueno NT. Inflammatory breast cancer: What we know and what we need to learn. Oncologist 17(7):891-9, 2012. e-Pub 5/14/2012. PMCID: PMC3399643.
73. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14(3):R83, 2012. e-Pub 5/23/2012. PMCID: PMC3446346.
74. Iyengar P, Strom EA, Zhang YJ, Whitman GJ, Smith BD, Woodward WA, Yu TK, Buchholz TA. The value of ultrasound in detecting extra-axillary regional node involvement in patients with advanced breast cancer. Oncologist 17(11):1402-1408, 2012. e-Pub 9/14/2012. PMCID: PMC3500360.
75. Smith BD, Jiang J, McLaughlin SS, Hurria A, Smith GL, Giordano SH, Buchholz TA. Improvement in breast cancer outcomes over time: Are older women missing out? J Clin Oncol 29(35):4647-53, 12/10/2011. e-Pub 11/7/2011. PMID: 22067407.
76. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, Hortobagyi GN, Gonzalez-Angulo AM, Luo S, Buzdar AU, Crow JR, Kuerer HM, Hunt KK. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first invervention: Time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol 29(35):4654-61, 12/10/2011. e-Pub 11/14/2011. PMCID: PMC3236648.
77. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117(24):5476-84, 12/15/2011. e-Pub 6/28/2011. PMID: 21713757.
78. Nagar H, Mittendorf EA, Strom EA, Perkins GH, Oh JL, Tereffe W, Woodward WA, Gonzalez-Angulo AM, Hunt KK, Buchholz TA, Yu TK. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically-staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys 81(3):782-7, 11/2011. e-Pub 8/2011. PMID: 21885207.
79. Wang L, Mason KA, Ang KK, Buchholz T, Valdecanas D, Mathur A, Buser-Doepner C, Toniatti C, Milas L. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. e-Pub 11/2011. PMID: 22127459.
80. Chavez-MacGregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi GN, Buchholz TA, Shih YC, Giordano SH. Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol 22(11):2394-2402, 11/2011. PMID: 21393379.
81. Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE. MK-1775, a novel Wee1 kinase inhibitor, radiosensitized p53-defective human tumor cells. Clin Cancer Res 17(17):5638-48, 9/1/2011. e-Pub 7/28/2011. PMCID: PMC3167033.
82. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations concerning implementation of the findings from the ACOSOG Z0011 Study. Ann Surg Oncol 18(9):2407-12, 9/2011. e-Pub 2/2011. PMID: 21327455.
83. Wang X, Amos RA, Zhang X, Taddei PJ, Woodward WA, Hoffman KE, Yu TK, Tereffe W, Oh J, Perkins GH, Salehpour M, Zhang SX, Sun TL, Gillin M, Buchholz TA, Strom EA. External-Beam Accelerated Partial Breast Irradiation Using Multiple Proton Beam Configurations. Int J Radiat Oncol Biol Phys 80(5):1464-72, 8/1/2011. e-Pub 8/12/2010. PMID: 20708848.
84. Reddy JP, Levy L, Oh JL, Strom EA, Perkins GH, Buchholz TA, Woodward WA. Long-term outcomes in patients with isolated supraclavicular nodal recurrence after mastectomy and Doxorubicin-based chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys 80(5):1453-7, 8/1/2011. e-Pub 12/16/2010. PMID: 21168284.
85. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628-34, 7/2011. PMCID: PMC3139370.
86. Albert JM, Buzdar AU, Guzman R, Allen PK, Strom EA, Perkins GH, Woodward WA, Hoffman KE, Tereffe W, Hunt KK, Buchholz TA, Oh JL. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat 128(2):421-7, 7/2011. e-Pub 5/8/2011. PMID: 21553292.
87. Shirvani SM, Pan IW, Buchholz TA, Shih YC, Hoffman KE, Giordano SH, Smith BD. Impact of evidence-based clinical guidelines on the adoption of postamastectomy radiation in older women. Cancer. e-Pub 6/27/2011. PMID: 21710653.
88. Smith BD, Pan IW, Shih YC, Smith GL, Harris JR, Punglia R, Pierce LJ, Jagsi R, Hayman JA, Giordano SH, Buchholz TA. Adoption of intensity modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst 103(10):798-809, 5/18/2011. e-Pub 4/27/2011. PMID: 21525437.
89. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117(9):1819-26, 5/2011. e-Pub 11/2010. PMID: 21509759.
90. Buchholz TA. Radiation in the setting of marked cytoreduction: do we radiate a cleared nodal basin or breast? ASCO Educational Book, 5/2011.
91. Shih YC, Chien CR, Xu Y, Pan IW, Smith GL, Buchholz TA. Economic burden of renal cell carcinoma: Part I--an updated review. Pharmacoeconomics 29(4):315-329, 4/2011. PMID: 21395351.
92. Shih YC, Chien CR, Xu Y, Pan IW, Smith GL, Buchholz TA. Economic burden of renal cell carcinoma in the US: Part II--an updated analysis. Pharmacoeconomics 29(4):331-41, 4/2011. PMID: 21395352.
93. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg 253(3):572-579, 3/2011. e-Pub 1/2011. PMID: 21209588.
94. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthpy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22(3):515-523, 3/2011. PMID: 20603440.
95. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist 16(12):1675-83, 2011. e-Pub 12/2011. PMID: 22147002.
96. Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, Woodward W, Buchholz TA, Hortobagyi GN, Cristofanilli M. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol 21(12):2348-55, 12/2010. e-Pub 5/3/2010. PMID: 20439340.
97. Smith BD, Haffty BG, Wilson LD, Smith GL, Patel AN, Buchholz TA. The Future of Radiation Oncology in the United States From 2010 to 2020: Will Supply Keep Pace With Demand? J Clin Oncol 28(35):5160-5165, 12/2010. PMID: 20956628.
98. Walker GV, Smith GL, Perkins GH, Oh JL, Woodward W, Yu TK, Hunt KK, Hoffman K, Strom EA, Buchholz TA. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer 116(17):4000-6, 9/1/2010. e-Pub 6/2010. PMID: 20564117.
99. Woodward WA, Truong PT, Yu TK, Tereffe W, Oh J, Perkins G, Strom E, Meric-Bernstam F, Gonzalez-Angulo AM, Speers C, Ragaz J, Buchholz TA. Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Res Treat 123(2):597-605, 9/2010. e-Pub 3/20/2010. PMID: 20306128.
100. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ, American Society of Clinical Oncology. American Society of Clinical Oncology Practice Guideline: 2009 update on adjuvant endocrine therapy for women with hormone-receptor positive breast cancer. J Clin Oncol 28(23):3784-3796, 8/10/2010. e-Pub 7/12/2010. PMID: 20625130.
101. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Strom EA, Tereffe W, Woodward WA, Tucker SL, Hunt KK, Hortobagyi GN, Buchholz TA. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys 77(5):1296-1302, 8/1/2010. e-Pub 5/14/2010. PMID: 20472353.
102. Zhang YJ, Oh JL, Whitman GJ, Iyengar P, Yu TK, Tereffe W, Woodward WA, Perkins G, Buchholz TA, Strom EA. Clinically apparent internal mammary nodal metastasis in patients with advanced breast cancer: Incidence and local control. Int J Radiat Oncol Biol Phys 77(4):1113-9, 7/15/2010. e-Pub 12/11/2009. PMID: 20004535.
103. Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Buchholz TA, Cristofanilli M, Reuben JM, Lewis MT, Woodward WA. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer 9(1). e-Pub 7/2010. PMID: 20615238.
104. Dawood S, Gonzalez-Angulo AM, Albarracin C, Yu TK, Hortobagyi GN, Buchholz TA, Woodward WA. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer 116(13):3084-92, 7/2010. PMID: 20564633.
105. Han CH, Lu J, Wei Q, Bondy ML, Brewster AM, Yu TK, Buchholz TA, Arun BK, Wang LE. The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat 122(1):243-9, 7/2010. e-Pub 12/2009. PMCID: PMC2883663.
106. Homann KL, Gates E, Salehpour M, Followill DS, Kirsner SM, White A, Buchholz TA, Prado KL. Use of a matchline dosimetry analysis tool (MDAT) to quantify dose homogeneity in the region between abutting radiation fields. J Appl Clin Med Phys 11(4):3294, 7/2010. PMID: 21081889.
107. Greenbaum MP, Strom EA, Allen PK, Perkins GH, Oh JL, Tereffe W, Yu TK, Buchholz TA, Woodward WA. Low locoregional recurrence rates in patients treated after 2000 with doxorubicin based chemotherapy, modified radical mastectomy, and post-mastectomy radiation. Radiother Oncol 95(3):312-6, 6/2010. e-Pub 3/2010. PMID: 20227126.
108. Woodward WA, Debeb BG, Xu W, Buchholz TA. Overcoming radiation resistance in inflammatory breast cancer. Cancer 116(11 Suppl):2840-5, 6/2010. PMID: 20503417.
109. Cristofanilli M, Buchholz TA. Proceedings of the first international inflammatory breast cancer conference. Cancer 116(11 Suppl):2729, 6/2010. PMID: 20503400.
110. Kaufmann M, Morrow M, von Minckwitz G, Harris JR, and The Biedenkopf Expert Panel Members (i.e. Buchholz TA, et al). Locoregional treatment of primary breast cancer: Consensus recommendations from an international expert panel. Cancer 1(116(5)):1184-1191, 3/2010. PMID: 20087962.
111. Smith GL, Shih YC, Xu Y, Giordano SH, Smith BD, Perkins GH, Tereffe W, Woodward WA, Buchholz TA. Racial disparities in the use of radiotherapy after breast-conserving surgery: A national Medicare study. Cancer 116(3):734-41, 2/1/2010. e-Pub 1/2010. PMID: 20014181.
112. Smith GL, Shih YC, Giordano SH, Smith BD, Buchholz TA. A method to predict breast cancer stage using Medicare claims. Epidemiol Perspect Innov 7:1, 2010. PMCID: PMC2818641.
113. Robertson FM, Bondy M, Yang WT, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player A, Barsky S. Woodward WA, Buchholz TA, Lucci A, Ueno NT, Cristofanilli M. Inflammatory Breast Cancer: the disease, the biology, the treatment. CA Cancer J Clin 60(6):351-375, 2010. PMID: 20959401.
114. Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, Spaeth E, Xu W, Zhang X, Lewis MT, Reuben JM, Krishnamurthy S, Ferrari M, Gaspar R, Buchholz TA, Cristofanilli M, Marini F, Andreeff M, Woodward WA. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal andmalignant breast cells. PLoS One 5(8), 2010. PMCID: PMC2922340.

Last updated: 2/16/2015